Corvex (MOVE) Proxy filing summary

Executive summary

• The proxy statement covers the 2026 annual meeting, including the election of directors, approval of equity issuances related to a recent merger, ratification of auditors, and new equity and employee stock purchase plans.

• The company completed a merger with Corvex OpCo, resulting in a new capital structure and a shift in business focus to AI cloud computing and legacy healthcare.

• The board determined the merger was the best strategic alternative after reviewing other options, including liquidation and alternative transactions.

• The merger was structured to ensure continued Nasdaq listing and to maximize shareholder value.

Voting matters and shareholder proposals

• Seven proposals are up for vote: election of two directors, approval of share issuances for preferred stock conversion and option/RSU vesting, auditor ratification, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and potential adjournment to solicit more proxies.

• Board recommends voting FOR all proposals.

• Approval of share issuances is required to comply with Nasdaq rules due to the size of the merger-related equity grants and potential change of control.

Board of directors and corporate governance

• Post-meeting board will have five members in staggered three-year terms, with three independent directors.

• New board composition reflects merger agreements, with representation from both legacy and new management.

• Board committees (Audit, Compensation, Nominating/Governance) are composed solely of independent directors.

• The company maintains a code of conduct, insider trading policy, and a clawback policy for executive compensation.